Harrow, Inc. shares drop over 50% since November 2024

Shares of Harrow, Inc., a company focusing on ophthalmology, have dropped more than 50% since November 2024. The fall followed a financial report for the third quarter of 2024, which showed a sales increase of only 1%. This was below what analysts expected. A shortage of inventory for their dry eye treatment, Vevye, contributed to the decline. Investors and traders have been discussing strategies related to buying and writing options for Harrow’s stock. Bret Jensen, a market analyst with over 13 years of experience, leads a group called The Biotech Forum. This group provides insights into appealing biotech stocks and offers resources like model portfolios, live chats, and weekly updates. It’s important to note that past performance of stocks does not guarantee future results. Investors should consider their individual situations before making investment decisions. There is no official recommendation in this article, and the opinions expressed may not represent those of the entire platform.